CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
MitraClip Proceduredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04350372
NCT04350372N/ACompleted

The MitraClip Russia Trial: A Prospective, Single-Center, Single-Arm Clinical Evaluation of the MitraClip System for the Treatment of Mitral Regurgitation

Abbott Medical Devices·interventional·Posted Apr 17, 2020·Updated Jun 14, 2022

In Brief

A clinical study evaluating MitraClip Procedure for Functional Mitral Regurgitation and Degenerrative Mitral Regurgitation. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The MitraClip System is the first commercially available catheter-based option for the treatment of MR. The MitraClip System was developed as an alternate percutaneous technology which may serve as a viable therapeutic option for patients at high risk for open-heart surgery. Treatment with the MitraClip device allows patients to undergo a less invasive procedure that can mechanistically reduce MR and allow for improved quality of life. The MitraClip procedure is performed under general anesthesia without the use of a heart-lung machine, with recovery typically lasting two to three days. The objective of this study is to evaluate safety and effectiveness of the MitraClip NT procedure in the Russian population for treatment of Mitral Regurgitation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesRussia
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedApr 17, 2020
Enrollment StartFeb 18, 2020
Primary CompletionSep 24, 2020
Study CompletionOct 2, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.2 years ago

Interventions

MitraClip Proceduredevice

MitraClip procedure with MitraClip NT System